PEAKS OF TRANSFORMING GROWTH FACTOR-?? mRNA IN ALVEOLAR CELLS OF LUNG TRANSPLANT RECIPIENTS AS AN EARLY MARKER OF CHRONIC REJECTION

Jm, Charpin; Valcke, Judith; Kettaneh, Laurence; Epardeau, B; Stern, M.; Israël‐Biet, Dominique

doi:10.1097/00007890-199803150-00027

Cited by 54 publications

(16 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…ET-1 has profibrotic properties and is involved in the airway remodelling of several inflammatory diseases. As in the heterotopic airway model in animals, increased BAL concentrations of MCP-1 [99], RANTES [102] and growth factors (PDGF [118], IGF-1 [119], and TGF-b [115,[120][121][122]) are found in human BOS. These profibrotic cytokines are responsible for an increased fibroblast-proliferative activity in BAL supernatant [123].…”

Section: Human Studiesmentioning

confidence: 88%

Post-transplant bronchiolitis obliterans

Boehler

Estenne²

2003

Eur Respir J

179

105

View full text Add to dashboard Cite

Over the last decade, improvements in surgical techniques, lung preservation, immunosuppression, and management of ischaemia/reperfusion injury and infections have made intermediate-term survival after lung transplantation an achievable goal. However, chronic allograft dysfunction in the form of bronchiolitis obliterans remains a major hurdle that threatens both the quality of life and long-term survival of the recipients. It affects up to 50-60% of patients who survive 5 yrs after surgery, and it accounts for w30% of all deaths occurring after the third postoperative year.This article discusses the alloimmune-dependent and -independent risk factors for bronchiolitis obliterans, the current understanding of the pathogenesis of bronchiolitis obliterans based on results of animal and human studies, the clinical staging of the complication, strategies that may contribute to the prevention and/or early detection of bronchiolitis obliterans, and suggestions for future research.

show abstract

Section: Human Studiesmentioning

confidence: 88%

Post-transplant bronchiolitis obliterans

Boehler

Estenne²

2003

Eur Respir J

179

105

View full text Add to dashboard Cite

show abstract

“…At some stage of OAD pathogenesis, alloimmune injury wanes and TGF-b 1 -dependent components of tissue remodeling are activated. Although TGF-b 1 is thought to have desirable antiinflammatory properties, increased levels of TGFb 1 in patients with OB appear to correlate with the severity of the disease (38,39). TGF-b 1 is a critical factor known to induce myofibroblast transdifferentiation (40).…”

Section: Discussionmentioning

confidence: 99%

Alcohol Ingestion by Donors Amplifies Experimental Airway Disease after Heterotopic Transplantation

Mitchell¹,

Guidot²

2007

Am J Respir Crit Care Med

View full text Add to dashboard Cite

“…Markers of granulocyte activation in BAL fluid have also been identified before or concurrently with the development of OB/BOS (125,126). In addition, profibrotic cytokines have been identified in BAL fluid from these patients (127,128).…”

Section: Chronic Allograft Dysfunction: Ob/bos Markers Mechanisms Pmentioning

confidence: 99%

Lung Transplantation: Opportunities for Research and Clinical Advancement

Wilkes¹

2006

Am J Respir Crit Care Med

View full text Add to dashboard Cite

Lung transplantation is the only definitive therapy for many forms of end-stage lung diseases. However, the success of lung transplantation is limited by many factors: (1 ) Too few lungs available for transplantation due to limited donors or injury to the donor lung; (2 ) current methods of preservation of excised lungs do not allow extended periods of time between procurement and implantation; (3 ) acute graft failure is more common with lungs than other solid organs, thus contributing to poorer short-term survival after lung transplant compared with that for recipients of other organs; (4 ) lung transplant recipients are particularly vulnerable to pulmonary infections; and (5 ) chronic allograft dysfunction, manifest by bronchiolitis obliterans syndrome, is frequent and limits long-term survival. Scientific advances may provide significant improvements in the outcome of lung transplantation. The National Heart, Lung, and Blood Institute convened a working group of investigators on June 14-15, 2004, in Bethesda, Maryland, to identify opportunities for scientific advancement in lung transplantation, including basic and clinical research. This workshop provides a framework to identify critical issues related to clinical lung transplantation, and to delineate important areas for productive scientific investigation. Keywords: allograft dysfunction; infection; ischemia-reperfusion injury; lung transplantation; obliterative bronchiolitis; rejectionThe transplantation of organs offers the promise of life-saving and life-enhancing therapy for a variety of ailments. Lung transplantation (LTx) has become an acceptable therapy to palliate patients with a variety of end-stage lung diseases. However, lung transplantation has not turned out to be a panacea for chronic lung disease because of significant limitations in the entire transplant process (Figure 1). First, there are not nearly enough suitable donor lungs to meet the needs of all patients with end-stage lung disease. As a result, more patients die waiting for transplants than from mortality associated with a lung transplant. Second, early graft survival after LTx is worse than for other types of organs transplanted (1). Finally, late survival after successful LTx is hampered by the development of chronic allograft dysfunction and by the life-limiting complications associated with conventional immunosuppressive medications. Two factors impede progress to address these problems: (1 ) lung transplant centers lack the infrastructure to facilitate prospective, multicenter clinical studies of sufficient power to address clinical questions and (2 ) there are too few investigators studying the biology of lung transplantation.The NHLBI convened a workshop on June 14-15, 2004, to better understand these complex problems and to identify strategies to address these and prioritize them. The topics addressed by participants were wide-ranging. They included the following: lung use rates from conventional brain-dead organ donors; safe limits for donor lung function; consideration o...

show abstract

PEAKS OF TRANSFORMING GROWTH FACTOR-?? mRNA IN ALVEOLAR CELLS OF LUNG TRANSPLANT RECIPIENTS AS AN EARLY MARKER OF CHRONIC REJECTION

Abstract: Our data suggest that TGF-beta expression in alveolar cells could serve as an early predictive and prognostic marker of chronic lung rejection.

Cited by 54 publications

References 8 publications

Post-transplant bronchiolitis obliterans

Post-transplant bronchiolitis obliterans

Alcohol Ingestion by Donors Amplifies Experimental Airway Disease after Heterotopic Transplantation

Lung Transplantation: Opportunities for Research and Clinical Advancement

Contact Info

Product

Resources

About